参考资料:
[1]苏延军,胡小军,李改英,等.高球蛋白血症268例鉴别诊断[J].中国现代医药杂志.2017,19(5):58-60.
[2]Rasel M,Zahra F. Hypergammaglobulinemia(Polyclonal Gammopathy)[Updated 2022 Sep 23]. In:StatPearls[Internet]. Treasure Island(FL): StatPearls Publishing; 2022 Jan-.Available from: https:// www.ncbi.nlm.nih. gov/books/NBK585137/
[3]Zhao EJ,Cheng CV,Mattman A, et al. Polyclonal hypergammaglobulinaemia: assessment,clinical interpretation, and management[J].Lancet Haematol. 2021,8(5): e365-e375.
[4]杨丹丹,张杰.高球蛋白血症性紫癜并发原发性干燥综合征一例[J].中国麻风皮肤病杂志,2019,35(2):92-95.
[5]Manns MP,Czaja AJ,Gorham JD,et al. Diagnosis and management of autoimmune hepatitis[J]. Hepatology.2010,51(6):2193-213.
[6]中华医学会肝病学分会.原发性胆汁性胆管炎的诊断和治疗指南(2021)[J].临床肝胆病杂志,2022,38(1):35-41.
[7]Shiboski CH,Shiboski SC,Seror R,et al.2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome:A consensus and data-driven methodology involving three international patient cohorts[J].Ann Rheum Dis.2017,76(1):9-16.
[8]Yan Y,Mei L,FuYe Q,et al. Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC/EGR1 axis[J].Arthritis Research&Therapy. 2019,21:92.
[9]王雪,袁祥,王其凯,等.艾拉莫德对原发性干燥综合征的治疗作用及其机制[J].中华疾病控制杂志.2018,1:75-78.
[10]Chen H,Qi X,Li Y,et al.Iguratimod treatment reduces disease activity in early primary Sjögren's syndrome: An open-label pilot study[J].Mod Rheumatol. 2021,31(2):394-398.
[11]Jiang W,Zhang L,Zhao Y,et al.The efficacy and mechanism for action of iguratimod in primary Sjögren's syndrome patients[J].Int Ophthalmol. 2020,40(11):3059-3065.
[12]Manns MP,Lohse AW,Vergani D. Autoimmune hepatitis--Update 2015[J]. J Hepatol.2015,62(1 Suppl): S100-11.
此文仅用于向医疗卫生专业人士提供科学信息,不代表平台立场。